Almost any growth of
tumors is to some extent associated with an inflammatory reaction which may be anti-tumorigenic by acting directly on
tumor cells or protumorigenic cells presumably by inducing
tumor-associated angiogenesis. In this study, we have analyzed the angiogenesis-inducing capacity of
monocyte chemoattractant protein-1 (MCP-1), a key regulatory molecule of monocyte trafficking to sites of
inflammation. MCP-1 was found to be potently angiogenic when implanted into rabbit cornea, exerting potency similar to the specific angiogenic
vascular endothelial growth factor (VEGF)-A(121). MCP-1-induced angiogenesis in the cornea is associated with prominent recruitment of macrophages, whereas VEGF-A(121)-induced
corneal angiogenesis is devoid of inflammatory cell recruitment. Based on these findings, we studied MCP-1 expression and macrophage recruitment in human invasive ductal mammary
carcinomas in comparison with the physiological angiogenic processes in bovine ovarian corpus luteum. Macrophage recruitment was always associated with MCP-1 expression. High macrophage counts in mammary
tumors corresponded with poor prognosis. In contrast, physiological ovarian angiogenesis was associated with only minimal inflammatory recruitment of macrophages. Our data show that MCP-1 is an indirect
inflammation-associated inducer of angiogenesis and demonstrate distinct qualitative differences between
tumor angiogenesis in human mammary
tumors and physiological angiogenesis in the ovary.